Belantamab mafodotin-associated corneal deposits on swept-source anterior segment optical coherence tomography and slit-lamp examination
A 78-year-old woman with relapsed IgG-kappa multiple myeloma developed bilateral blurred vision and monocular diplopia 21 days after starting the BelaPd regimen. Slit-lamp examination revealed bilateral subepithelial corneal deposits on direct illumination (Figure 1A, left eye) and retroillumination (Figure 1B, right eye), graded 2–3 according to the KVA scale(1). Anterior segment optical coherence tomography showed microcyst-like epithelial changes, predominantly in the peripheral and paracentral cornea (Figure 1C, right eye, and Figure 1D, left eye)(2,3). The Bowman layer was preserved. The keratopathy resolved 2 months after belamaf was withheld.
Funding:
Data Availability Statement:
The datasets generated and/or analyzed during the current study are included in the manuscript.
REFERENCES
- 1 Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.
- 2 Mencucci R, Cennamo M, Alonzo L, Senni C, Vagge A, Ferro Desideri L, et al. Corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging. J Clin Med. 2022;11(10):2884.
- 3 Matsumiya W, Karaca I, Ghoraba H, Akhavanrezayat A, Mobasserian A, Hassan M, et al. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. Am J Ophthalmol Case Rep. 2021;23:101133.
